Replies to post #724812 on NorthWest Biotherapeutics Inc (NWBO)

[manibiotech]

Well wait for someone to respond with “ you don’t understand the revolutionary science “ wait for combo results “ , “ it’s all about science “

There is a group here that defends no matter what , lack of ROI is of no consequence to them . It is almost an alien concept for them .

[XMaster2023]

For someone who hopes for the future, you have a bleak outlook on life. As I have said before, I believe they are currently fabricating the vaccine as we speak as they changed the status to HUMAN. Advent just cannot distribute it. They have a fixed overhead cost why have employees just sitting around?

[CherryTree1]

You should have kept buying all the way down. I picked up most of my share at just under 20 cents. ROI will be fantastic once approval comes hopefully very soon.

[Investor082]

ROI concept doesn’t exist. It always about averaging down and playing victim card!

Watch out for the Flaskworks carrot when the response to UK approval is muted, but they wont take accountability for the fact that they could have submitted reimbursement evidence 6-9 months ago given they have had 3-4 years since data lock to prepare for that. They wont accept responsibility for not applying to FDA when its 10X the market size as UK, 4 years since data lock.

Flaskworks will not be approved commercially until 2026 at the earliest and that too if everything goes according to plan. So be prepared for a ton of dilution over the next 18 months and share price to continue to slide after the momentary UK approval spike. Without reimbursement, they wont be generating meaningful revenue and no big pharma or institutional investor is interested in backing them. So forget about a buyout or even partnership with a big pharma. It would have happened by now, if there was any interest. The TLD and JAMA has been out for over 2 years. There are many big pharmas that would love to establish a dominant position in oncology or enter this highly lucrative space with a platform technology, but none of them see this as exciting or commercially viable. If this was a blockbuster product, they would have tried to outbid their competitor and partnered before their peers within a few months of TLD and JAMA release, and not wait 2 years. So don't fall for Flaskworks carrot!